Eye Drop Guidance Updates: Prime Therapeutics

Prime Therapeutics acquired Magellan Rx in 2022 and released the first “integrated” Provider Manual for network pharmacies in January 2024. An important change in the revised Provider Manual is the guidance for billing eye drop medications, which carries billing and audit implications.

Become an audit assistance member today to continue reading this article. As a member, you’ll have access to hundreds of articles and receive our monthly proactive newsletter!

Old Guidance: “Calculate eye drops days’ supply using 15 drops per mL for solutions and 12 drops per mL for suspensions.”

New Guidance: “Calculate eye drops days’ supply based on the specific product.”

This guidance is challenging, as there is no master list of eye drop medications where the drop/mL information is specified by the manufacturer. New eye drops are coming to market that are free of water and preservatives; consequently, the drop size is approximately 66% – 80% less than traditional eye drops (see example list below).  Absent this information, PAAS National® suggests that pharmacies use 20 drops per mL for solutions and 15 drops per mL for suspensions when products do not specify drops/mL.

Manufacturer Specific Drop per mL:

  1. Miebo® 272 drops per 3 mL (~90 drop per mL)
  2. Vevye® 200 drops per 2 mL (100 drop per mL)
  3. Vyzulta® 81 drops per 2.5 mL (~32 drop per mL)

PAAS Tips:

Eric Hartkopf, PharmD